GSK coughs up $2B for Bellus Health

GSK announced Tuesday morning that it is acquiring Canadian biopharma Bellus Health for $2 billion.

The apple of GSK’s eye in the deal is Camlipixant, a P2X3 antagonist in Phase 3 development for treating adult patients with refractory chronic cough (RCC).